08-dummy 1

Find Something You love

Lorem ipsum dolor sit amet, consectetuer adipiscin.

08-dummy 1

Find Something You love

Lorem ipsum dolor sit amet, consectetuer adipiscin.

08-dummy 1

Find Something You love

Lorem ipsum dolor sit amet, consectetuer adipiscin.

Shop By Category

Full Length Transmembrane Proteins
Full Length Transmembrane Proteins

1544 产品

ADC Assay Reagents
ADC Assay Reagents

4 产品

DiSliceX
DiSliceX

24 产品

Overexpression Stable Cell Line
Overexpression Stable Cell Line

103 产品

ECD Proteins
ECD Proteins

1822 产品

Monoclonal Antibodies
Monoclonal Antibodies

1156 产品

Biosimilar reference antibodies
Biosimilar reference antibodies

1446 产品

Latest Collections

Biosimilar reference antibodies

Anti-DNA(TMAB3,D31 biosimilar) mAb

SKU:  BME100285     Target:  DNA

Application:  N/A

Price: 50 μg ￥800.00 ; 100 μg ￥1500.00

Biosimilar reference antibodies

Anti-DNA(TMAB3,D31N biosimilar) mAb

SKU:  BME100284     Target:  DNA

Application:  N/A

Price: 50 μg ￥800.00 ; 100 μg ￥1500.00

Biosimilar reference antibodies

Anti-GREM1(ginisortamab biosimilar) mAb

SKU:  BME100266     Target:  GREM1

Application:  N/A

Price: 50 μg ￥800.00 ; 100 μg ￥1500.00

Biosimilar reference antibodies

Anti-CD3E(tarlatamab without DLL3 biosimilar) mAb

SKU:  BME100258     Target:  CD3E

Application:  N/A

Price: 50 μg ￥800.00 ; 100 μg ￥1500.00

Biosimilar reference antibodies

Anti-IL4(pascolizumab biosimilar) mAb

SKU:  BME100256     Target:  IL4

Application:  N/A

Price: 50 μg ￥800.00 ; 100 μg ￥1500.00

Biosimilar reference antibodies

Anti-IGHE(omalizumab biosimilar) mAb

SKU:  BME100247     Target:  IgHE

Application:  N/A

Price: 50 μg ￥800.00 ; 100 μg ￥1500.00

Biosimilar reference antibodies

Anti-FGF23(burosumab biosimilar) mAb

SKU:  BME100242     Target:  FGF23

Application:  N/A

Price: 50 μg ￥800.00 ; 100 μg ￥1500.00

Biosimilar reference antibodies

Anti-IL18(camoteskimab biosimilar) mAb

SKU:  BME100239     Target:  IL18

Application:  N/A

Price: 50 μg ￥800.00 ; 100 μg ￥1500.00

How it Works

Apply to be a Vendor

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat.

Upload your products

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat.

Sell and make money

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat.

Latest Reviews

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat….

Name / Lastname

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat….

Name / Lastname

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat….

Name / Lastname

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat….

Name / Lastname

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat….

Name / Lastname

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat….

Name / Lastname

From The Blog

2026 ASCO靶点盘点（三）：小分子靶向与精准治疗篇

EGFR、RET、RAS、ER、AR 等经典靶点持续进化，精准治疗…

17
6 月
2026 ASCO靶点盘点（二）：双抗、多抗与免疫联合篇

双抗研发正在从“两个靶点拼接”走向“机制协同”，CD3 重定向、P…

17
6 月
2026 ASCO靶点盘点（一）：ADC篇

HER2、TROP2 不再是唯一主角，CLDN18.2、B7-H3…

17
6 月
4-5月生物医药交易盘点：152亿美元授权、117.5亿美元并购领衔，全球医药BD金额再创新高

2026年4-5月全球生物医药交易回暖，大药企聚焦确定性资产，中国…

02
6 月
G蛋白偶联受体84/GPR84：连接代谢与免疫的新兴靶点

近年来，代谢-免疫交叉成为药物研发的重要方向，其中G蛋白偶联受体8…

12
5 月
TfR1/TFRC/CD71：从铁代谢到脑递送入口

2025年，罗氏更新trontinemab临床数据后，TfR1介导…

09
5 月
从血脑屏障穿梭机制看治疗性靶点：谁更有机会把药真正送进脑内？

血脑屏障（BBB）正成为神经系统药物递送的关键入口。随着 Tron…

23
4 月
从BD到临床：2026Q1自免赛道的真正主线浮出水面

2026年第一季度，自身免疫领域的进展不再是“零散创新”，而是围绕…

23
4 月